Publications: SRC7 and Ki67 Breast Cancer Working Group
Published:Category: Publications
SRC7 publication: Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. General review: Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Read More
Trial closure: SC24
Published:Category: Trials
The SC24 randomized phase II/III study comparing stereotactic body radiotherapy(SBRT) versus conventional palliative radiotherapy (CRT) for patients with spinal metastases has been permanently closed following primary publication.
Read MoreClosed to accrual: MAC23
Published:Category: Trials
MAC23 study, "RT CHARM:Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation with Breast Reconstruction" was closed to accrual after reaching its accrual target. This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
Read MoreCCTG is seeking a visionary cancer trialist to join our team as Senior Investigator
Published:Category: Group updates
CCTG is seeking an outstanding and visionary cancer trialist for the position of Senior Investigator (SI). Expertise in cancer clinical trial methods and conduct is required. Interest in investigational new drug trials, thoracic, gynecological, or genitourinary cancers is desirable but not required. As one of our Senior Investigators you will be co-principal investigator of individual trials, and leader within the CCTG program and the CCTG scientific committees. Senior Investigators also have Faculty appointments at Queen’s University.
Read MoreCIHR funding announced for CO29
Published:Category: News
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.
Read MorePublication: CCTG MYX1 secondary economic analysis
Published:Category: Publications
CCTG MYX1 (MCRN‐003): Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Descriptive Cost Analysis from the MCRN‐003/MYX1 single arm phase II trial
Closed to accrual: GA1
Published:Category: Trials
The CCTG GA1 | TOPGEAR a Randomized Phase II/III Trial of Preoperative Chemoradiotherapy versus Preoperative Chemotherapy For Resectable Gastric Cancer has closed to accrual after successfully reaching, and surpassing, the overall target accrual.
Read More
CCTG is hiring a Web Application Developer
Published:Category: Group updates
Reporting to the Information Technology (IT) Program Manager, the Web Application Developer is responsible for the entire project/software lifecycle which consists of the following components: application architecture, input/output design, system specifications, process mapping, user requirements, layouts, user interface, database design/programming, test plans and training.
Find out more and how to apply.
Read More